Merck & Co Given “Outperform” Rating at Sanford C. Bernstein (MRK)

Share on StockTwits

Merck & Co (NYSE: MRK)‘s stock had its “outperform” rating restated by equities research analysts at Sanford C. Bernstein in a research note issued to investors on Friday, AnalystRatingsNetwork reports. They currently have a $49.00 target price on the stock. Sanford C. Bernstein’s target price would suggest a potential upside of 2.30% from the company’s current price.

Merck & Co (NYSE: MRK) traded up 0.52% on Friday, hitting $48.15. Merck & Co has a 52-week low of $38.72 and a 52-week high of $50.16. The stock’s 50-day moving average is currently $46.92. The company has a market cap of $145.4 billion and a price-to-earnings ratio of 24.44.

Merck & Co (NYSE: MRK) last posted its quarterly earnings results on Wednesday, May 1st. The company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.06. The company had revenue of $10.70 million for the quarter, compared to the consensus estimate of $11.09 million. During the same quarter last year, the company posted $0.99 earnings per share. Merck & Co’s revenue was down 9.0% compared to the same quarter last year. Merck & Co has set its FY13 guidance at $3.45-3.55 EPS. On average, analysts predict that Merck & Co will post $3.50 earnings per share for the current fiscal year.

A number of other firms have also recently commented on MRK. Analysts at UBS AG raised their price target on shares of Merck & Co from $51.00 to $53.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Separately, analysts at TheStreet reiterated a “buy” rating on shares of Merck & Co in a research note to investors on Thursday, June 6th. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Merck & Co in a research note to investors on Wednesday, June 5th. They now have a $54.00 price target on the stock.

Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have issued a buy rating to the company. Merck & Co has a consensus rating of “Buy” and an average target price of $51.36.

The company also recently declared a quarterly dividend, which is scheduled for Monday, July 8th. Shareholders of record on Monday, June 17th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 3.59%. The ex-dividend date of this dividend is Thursday, June 13th.

Merck & Co, Inc. (NYSE: MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.

Latest News

Tiffany Sees Strong Sales Growth During Second Quarter
Tiffany Sees Strong Sales Growth During Second Quarter
HubSpot Planning an IPO of $100 Million
HubSpot Planning an IPO of $100 Million
Roche Acquires InterMune
Roche Acquires InterMune
Western Firms Getting Hit in Russia
Western Firms Getting Hit in Russia
U.S. Head of McDonald’s Replaced Again
U.S. Head of McDonald’s Replaced Again
Profit Surges at GameStop
Profit Surges at GameStop


Leave a Reply

 
 
© 2006-2014 Ticker Report. Google+.